Rationale, design and population baseline characteristics of the PERFORM Vascular Project

• Verfasst von: Hennerici, Michael G. [VerfasserIn]
• Verfasst von: Bots, Michiel L. [VerfasserIn]
• Verfasst von: Ford, Ian [VerfasserIn]
• Verfasst von: Laurent, Stéphane [VerfasserIn]
• Verfasst von: Touboul, Pierre Jean [VerfasserIn]
• Titel: Rationale, design and population baseline characteristics of the PERFORM Vascular Project
• Titelzusatz: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial
• Verf.angabe: Michael G. Hennerici, Michiel L. Bots, Ian Ford, Stéphane Laurent, Pierre Jean Touboul
• E-Jahr: 2010
• Jahr: 20 May 2010
• Umfang: 6 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 12.03.2021
• Titel Quelle: Enthalten in: Cardiovascular drugs and therapy
• Ort Quelle: Dordrecht [u.a.] : Springer Science + Business Media B.V, 1987
• Jahr Quelle: 2010
• Band/Heft Quelle: 24(2010), 2, Seite 175-180
• ISSN Quelle: 1573-7241
• DOI: doi:10.1007/s10557-010-6231-2
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1751234096

Abstract

Purpose - PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs). The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by change in carotid intima-media thickness (CIMT) in a subgroup of patients. - - Methods and results - The Vascular Project includes structural (CIMT, carotid plaques) and functional (carotid stiffness) vascular studies in all patients showing at least one carotid plaque at entry. Expected mean follow-up is 36 months. Primary endpoint is rate of change of CIMT. Secondary endpoints include emergent plaques and assessment of carotid stiffness. 1,100 patients are required for 90% statistical power to detect treatment-related CIMT difference of 0.025 mm. The first patient was randomized in April 2006. - - Conclusions - The PERFORM Vascular Project will investigate terutroban’s effect on vascular structure and function in patients with a history of ischemic stroke or TIAs.